Vitarka Therapeutics
3 known investors
Find your way into Vitarka Therapeutics
428 people in our graph share verified history with the Vitarka Therapeutics team — schools, employers, funds. One of them is your warm intro.
Richard Leeunlockedknows Vineeta Tripathi · together at University of Nottingham (overlapped)
×3knows the team · via University of the Witwatersrand
×4knows the team · via GSK
knows the team · via University of Nottingham
×3knows the team · via St. Xavier's College
Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.
Founders & leadership
VT
Vineeta TripathiinFounding CEOVineeta Tripathi has over 15 years of pharmaceutical drug development experience across neuroscience, immuno-oncology, and ophthalmology, with academic expertise in neurodegenerative disease mechanisms and a track record of published research and patent inventions in therapeutic biologics. She is co-founder and CEO of Vitarka Therapeutics, a biotechnology company developing intracellular drug delivery technology.
JB
John BeadleinCo-founderJohn Beadle is a physician with an MD and MBA who has held leadership roles including Founding CEO of PsiOxus, Founder and Chief Medical Officer of PowderMed, Site Head at Pfizer, and VP of Global Medical Operations at GlaxoSmithKline, with experience in nucleotide vaccines, stem cell therapies, gene therapies, and immuno-oncology.
Investors · 3
Companies House · registry record
View on Companies House ↗- Registered name
- VITARKA THERAPEUTICS LTD
- Company number
- 13291464
- Status
- Active
- Company type
- Private limited company
- Incorporated
- 25 Mar 2021
- Registered office
- Innovation House Innovation Way, Discovery Park, Sandwich, CT13 9FF
- Nature of business (SIC)
- 72110 — Research and experimental development on biotechnology
- Accounts
- last made up to 31 Dec 2025 · next due 30 Sept 2027
- Confirmation statement
- last made up to 24 Mar 2026 · next due 7 Apr 2027
Current officers · 4
- John William Beadle — director, appointed 11 Nov 2024
- James Duncan Bruce Faulkner — director, appointed 11 Mar 2024
- Mayer Schreiber — director, appointed 5 Apr 2022
- Vineeta Tripathi — director, appointed 25 Mar 2021
Source: Companies House public register · retrieved 23 Aug 2026. Contains public sector information licensed under the Open Government Licence v3.0.
In the news
Frequently asked questions
- What does Vitarka Therapeutics do?
- Vitarka Therapeutics develops ENDOPORE, a drug delivery technology designed to transport therapeutic molecules into cells to treat diseases including cancer. The company operates in the biotechnology sector, focusing on solving a key challenge in drug development by enabling treatment targets that previously could not be reached.
- Who founded Vitarka Therapeutics?
- Vitarka Therapeutics was founded by Vineeta Tripathi, John Beadle.
- Who are Vitarka Therapeutics's investors?
- Vitarka Therapeutics's investors include Future Planet Capital, UK Innovation & Science Seed Fund, SOSV.